Harzole-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, designed for the effective management of gastroesophageal reflux disease (GERD), acid reflux, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing sustained acid suppression and promoting mucosal healing. The synergistic action of these two agents in Harzole-DSR Capsule offers comprehensive relief from acid-related symptoms and enhances patient compliance by combining prokinetic and acid-suppressive therapies in a single dosage form. This combination is particularly beneficial for patients with erosive esophagitis, Zollinger-Ellison syndrome, or those requiring prolonged acid suppression alongside improved gastric motility. Harzole-DSR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with cardiac arrhythmias or hepatic impairment. Adverse effects may include headache, dry mouth, abdominal cramps, or diarrhea. Regular monitoring and adherence to prescribed dosage ensure optimal therapeutic outcomes.